Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of ARCT-154 versus COMIRNATY as a COVID-19 booster
jRCT2071220080Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing ARCT-154 booster with COMIRNATY booster (2 arms). Primary endpoints: Neutralizing antibody geometric mean on Day 29 against SARS-CoV-2 Wuhan strain and Seroresponse rate on Day 29 against SARS-CoV-2 Wuhan strain. Started Dec 2022; status: completed.
02
Drugs
ARCT-154tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071220080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220080.